Christopher Peetz Sells 40,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Key Points

• CEO Stock Sale: Mirum Pharmaceuticals CEO Christopher Peetz sold 40,000 shares of stock for $2.21 million, representing a 22.39% decrease in his holdings.
• Quarterly Earnings Beat: The company reported a loss of ($0.12) EPS, surpassing estimates of ($0.31) and achieving a quarterly revenue of $127.79 million, which was significantly above expectations.
• Analyst Ratings Update: While Wall Street Zen downgraded Mirum to a "hold" rating, other firms have set higher price targets, with Evercore ISI raising theirs from $77.00 to $89.00 and maintaining an "outperform" rating.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 40,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $55.25, for a total transaction of $2,210,000.00. Following the completion of the sale, the chief executive officer directly owned 138,641 shares of the company's stock, valued at approximately $7,659,915.25. This trade represents a 22.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Monday, August 11th, Christopher Peetz sold 40,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $62.00, for a total transaction of $2,480,000.00.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock traded up $1.08 on Wednesday, reaching $65.80. The company had a trading volume of 296,403 shares, compared to its average volume of 488,990. The stock has a market capitalization of $3.31 billion, a PE ratio of -54.45 and a beta of 0.94. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. Mirum Pharmaceuticals, Inc. has a one year low of $36.86 and a one year high of $67.45. The business's 50-day moving average is $51.65 and its 200 day moving average is $47.42.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.19. The business had revenue of $127.79 million during the quarter, compared to analyst estimates of $107.91 million. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The firm's quarterly revenue was up 64.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.52) EPS. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on MIRM. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. Stifel Nicolaus set a $89.00 target price on shares of Mirum Pharmaceuticals and gave the company a "buy" rating in a research note on Monday. Wall Street Zen raised shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Finally, JMP Securities set a $81.00 price objective on shares of Mirum Pharmaceuticals and gave the stock a "market outperform" rating in a research note on Thursday, August 7th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $74.13.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Mirum Pharmaceuticals by 4,555.0% in the 1st quarter. GAMMA Investing LLC now owns 5,586 shares of the company's stock valued at $252,000 after purchasing an additional 5,466 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Mirum Pharmaceuticals by 174.9% during the 1st quarter. SG Americas Securities LLC now owns 19,182 shares of the company's stock worth $864,000 after buying an additional 12,204 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Mirum Pharmaceuticals by 2.1% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company's stock worth $752,000 after buying an additional 339 shares during the period. MPM Bioimpact LLC grew its position in shares of Mirum Pharmaceuticals by 19.7% during the 4th quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock worth $24,379,000 after buying an additional 96,856 shares during the period. Finally, KBC Group NV acquired a new stake in shares of Mirum Pharmaceuticals during the 1st quarter worth approximately $89,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.